AlphaCentric Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

AlphaCentric Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$348K	Buy	+9,821	New	+$384K	0.31%	103

Other funds holding TRAX

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

AlphaCentric Advisors's TRAX Position: Q3 2026 in Review

AlphaCentric Advisors opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 9,821 shares worth $348K. The stake represents 0.31% of the portfolio and ranks #103 among its holdings.

43 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

AlphaCentric Advisors held 9,821 shares of First Tracks Biotherapeutics worth $348K as of Q3 2026.
First Tracks Biotherapeutics was a new AlphaCentric Advisors position in Q3 2026.
First Tracks Biotherapeutics made up 0.31% of AlphaCentric Advisors's portfolio in Q3 2026, its #103 holding.
43 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.